Erlocip 150 Tablet

1. Product Introduction

Erlocip 150 Tablet is a prescription anti-cancer medicine that contains Erlotinib (150mg) as its active ingredient. Erlotinib belongs to a class of targeted therapy drugs known as tyrosine kinase inhibitors (TKIs). It is specifically designed to inhibit the activity of the epidermal growth factor receptor (EGFR), which plays a crucial role in the growth and spread of certain types of cancer cells.

Manufactured by Cipla Ltd, Erlocip 150 is used as an oral chemotherapy agent, often prescribed in patients with non-small cell lung cancer (NSCLC) and pancreatic cancer, especially in cases where cancer has progressed after standard treatments or when patients have EGFR gene mutations.

This tablet is meant to be taken under strict medical supervision and is usually prescribed as part of a comprehensive cancer treatment plan tailored to individual needs.

2. Uses of This Medicine

Erlocip 150 Tablet is primarily used in the treatment of the following conditions:

• Non-Small Cell Lung Cancer (NSCLC):

  • Erlocip is widely used in patients with NSCLC who have specific EGFR gene mutations.

  • It is often prescribed when the cancer has metastasized (spread) or is locally advanced, especially after the failure of other chemotherapy treatments.

• Pancreatic Cancer:

  • In combination with gemcitabine, Erlocip is used in the treatment of advanced pancreatic cancer to help slow the progression of the disease.

• Other Off-Label Uses:

  • In some cases, doctors may use Erlocip in other cancers where EGFR expression is present, though such uses are off-label and depend on clinical judgment.

The medicine works best in cancers that have specific mutations in the EGFR gene, and doctors may conduct genetic testing before prescribing it.

3. Benefits of This Medicine

Erlocip 150 offers several clinical advantages in the fight against certain types of cancer:

• Targeted Therapy:
  Unlike traditional chemotherapy, Erlocip specifically targets cancer cells with abnormal EGFR protein activity, reducing harm to normal healthy cells.

• Delays Disease Progression:
  It helps in delaying tumor growth and progression in EGFR-mutated NSCLC and pancreatic cancer, improving progression-free survival.

• Oral Administration:
  Erlocip is taken orally, making it more convenient for patients compared to intravenous chemotherapy.

• Effective in Resistant Cases:
  For patients who do not respond to first-line chemotherapy, Erlocip provides an effective second-line or maintenance therapy option.

• Improved Quality of Life:
  By slowing disease progression and reducing tumor size, patients often experience symptomatic relief, including improved breathing, appetite, and energy levels.

• Tolerable Side Effect Profile:
  Though not without side effects, targeted therapies like Erlotinib are generally better tolerated compared to traditional chemotherapies.

4. Side Effects

Like all cancer medications, Erlocip 150 Tablet can cause side effects, although not everyone will experience them. Some side effects are manageable with dose adjustments or supportive treatments.

Common Side Effects:

• Skin rash (acne-like or dry skin)

• Diarrhea

• Loss of appetite

• Nausea and vomiting

• Fatigue

• Weakness

• Itching or dryness of the skin

• Hair thinning

Serious Side Effects:

• Interstitial lung disease (rare but serious – signs include shortness of breath or cough)

• Liver function abnormalities (increased liver enzymes)

• Gastrointestinal perforation (very rare)

• Severe skin reactions

• Eye irritation (e.g., conjunctivitis or dry eyes)

Patients should report any new or worsening symptoms to their doctor promptly. Regular blood tests are usually required to monitor liver function and other parameters during treatment.

5. Frequently Asked Questions (FAQ)

Q1. How should I take Erlocip 150 Tablet?

A: Take Erlocip 150 on an empty stomach, at least 1 hour before or 2 hours after meals. Swallow the tablet whole with water. Always follow your doctor’s instructions regarding dose and duration.

Q2. Can Erlocip 150 cure cancer?

A: Erlocip is not a cure but a treatment that helps slow cancer progression and may shrink tumors. It is most effective in patients with EGFR-mutated cancers and can significantly improve quality of life and survival.

Q3. What if I miss a dose?

A: If you miss a dose, take it as soon as you remember. However, if it’s close to your next scheduled dose, skip the missed one. Do not double the dose to make up for the missed one.

Q4. Can I take Erlocip 150 during pregnancy or breastfeeding?

A: No. Erlocip can harm the unborn baby and should not be taken during pregnancy or breastfeeding. Effective contraception should be used during treatment and for a few weeks after stopping the medication.

Q5. How long do I need to take Erlocip 150?

A: The duration depends on how well your cancer responds and your tolerance to the medicine. Your oncologist will assess your progress through scans and blood tests and adjust the duration accordingly.